INVA Innoviva, Inc.
USHealthcareAs of 2026-07-10 16:00
Why INVA matters now
Innoviva, Inc. (INVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $22.24 with +0.18% on the session and $1.64B in market capitalization; recent performance reads 1-month +3.50% and YTD +12.51%.
The latest financial table shown here is Q1 2026, with revenue of $98.0M, net income of $186.6M, and EPS of $2.22. Investors can compare that operating picture with valuation signals such as P/E 5.64 and FCF yield 10.9%.
The latest indexable market news headline is "Nortiva Bio Launches to Develop Long-Acting Oral Medicines" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $37.00; recent insider activity includes Zhen Marianne filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
5.64
PEG
0.01
P/B
1.24
P/S
3.91
EV/EBITDA
2.17
DCF Value
$64.77
FCF Yield
10.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.2%
Operating Margin
14.8%
Net Margin
118.9%
ROE
47.6%
ROA
27.5%
ROIC
2.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $98.0M | $186.6M | $2.22 |
| Q4 2025 | $118.0M | $164.2M | $1.94 |
| FY 2025 | $425.1M | $271.2M | $3.30 |
| Q3 2025 | $107.8M | $89.9M | $1.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$37.00
Target (Median)
$37.00
Target Range
$32.00 - $42.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.35
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.